Advertisement

47-Year-Old Given BCG Vaccine as a Child

  • Michael P. Lee
  • Kevin K. Wu
  • Jashin J. Wu
Chapter
Part of the Clinical Cases in Dermatology book series (CLIDADE)

Abstract

Immunosuppressive therapy for psoriasis such as TNF inhibitors can increase the risk of tuberculosis. Patients should be screened for latent tuberculosis infection with a PPD skin test or IGRA. Those who have previously received the BCG vaccine should have an IGRA due to the chance of false positives. This was a case of a 47-year-old Filipino male with a history of BCG vaccine as a child.

Keywords

Psoriasis BCG vaccine Tuberculosis 

References

  1. 1.
    Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, Gottlieb AB, Koo JY, Lebwohl M, Lim HW, Van Voorhees AS, Beutner KR, Bhushan R. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol. 2009;61(3):451–85.  https://doi.org/10.1016/j.jaad.2009.03.027.CrossRefPubMedGoogle Scholar
  2. 2.
    Fotiadou C, Lazaridou E, Ioannides D. Safety of anti-tumour necrosis factor-alpha agents in psoriasis patients who were chronic hepatitis B carriers: a retrospective report of seven patients and brief review of the literature. J Eur Acad Dermatol Venereol. 2011;25(4):471–4.  https://doi.org/10.1111/j.1468-3083.2010.03754.x.CrossRefPubMedGoogle Scholar
  3. 3.
    Keane J. TNF-blocking agents and tuberculosis: new drugs illuminate an old topic. Rheumatology (Oxford). 2005;44(6):714–20.  https://doi.org/10.1093/rheumatology/keh567.CrossRefGoogle Scholar
  4. 4.
    Getahun H, Matteelli A, Chaisson RE, Raviglione M. Latent Mycobacterium tuberculosis infection. N Engl J Med. 2015;372(22):2127–35.  https://doi.org/10.1056/NEJMra1405427.CrossRefPubMedGoogle Scholar
  5. 5.
    Brassard P, Kezouh A, Suissa S. Antirheumatic drugs and the risk of tuberculosis. Clin Infect Dis. 2006;43(6):717–22.  https://doi.org/10.1086/506935.CrossRefPubMedGoogle Scholar
  6. 6.
    Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001;345(15):1098–104.  https://doi.org/10.1056/NEJMoa011110.CrossRefPubMedGoogle Scholar
  7. 7.
    Gardam MA, Keystone EC, Menzies R, Manners S, Skamene E, Long R, Vinh DC. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis. 2003;3(3):148–55.CrossRefGoogle Scholar
  8. 8.
    Mazurek GH, Jereb J, Vernon A, LoBue P, Goldberg S, Castro K, IGRA Expert Committee; Centers for Disease Control and Prevention (CDC). Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection—United States, 2010. MMWR Recomm Rep. 2010;59(RR-5):1–25.PubMedGoogle Scholar
  9. 9.
    Koca R, Altinyazar HC, Numanoglu G, Unalacak M. Guttate psoriasis-like lesions following BCG vaccination. J Trop Pediatr. 2004;50(3):178–9.  https://doi.org/10.1093/tropej/50.3.178.CrossRefPubMedGoogle Scholar
  10. 10.
    Takayama K, Satoh T, Hayashi M, Yokozeki H. Psoriatic skin lesions induced by BCG vaccination. Acta Derm Venereol. 2008;88(6):621–2.  https://doi.org/10.2340/00015555-0496.CrossRefPubMedGoogle Scholar
  11. 11.
    Centers for Disease Control and Prevention. Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection. MMWR Morb Mortal Wkly Rep. 2011;60(48):1650–3.Google Scholar
  12. 12.
    Wallis RS, Broder M, Wong J, Beenhouwer D. Granulomatous infections due to tumor necrosis factor blockade: correction. Clin Infect Dis. 2004;39(8):1254–5.  https://doi.org/10.1086/424455.CrossRefPubMedGoogle Scholar
  13. 13.
    Menter A, Thaci D, Papp KA, Wu JJ, Bereswill M, Teixeira HD, Rubant S, Williams DA. Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis. J Am Acad Dermatol. 2015;73(3):410–419 e416.  https://doi.org/10.1016/j.jaad.2015.06.038.CrossRefPubMedGoogle Scholar
  14. 14.
    Doherty SD, Van Voorhees A, Lebwohl MG, Korman NJ, Young MS, Hsu S, National Psoriasis F. National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents. J Am Acad Dermatol. 2008;59(2):209–17.  https://doi.org/10.1016/j.jaad.2008.03.023.CrossRefPubMedGoogle Scholar
  15. 15.
    Tsai TF, Ho V, Song M, Szapary P, Kato T, Wasfi Y, Li S, Shen YK, Leonardi C, Phoenix PAP, Japanese Ustekinumab Study Group. The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection. Br J Dermatol. 2012;167(5):1145–52.  https://doi.org/10.1111/j.1365-2133.2012.11142.x.CrossRefPubMedGoogle Scholar
  16. 16.
    Griffiths CE, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A, Cameron GS, Erickson J, Zhang L, Secrest RJ, Ball S, Braun DK, Osuntokun OO, Heffernan MP, Nickoloff BJ, Papp K, UNCOVER-2 and UNCOVER-3 investigators. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386(9993):541–51.  https://doi.org/10.1016/S0140-6736(15)60125-8.CrossRefPubMedGoogle Scholar
  17. 17.
    van de Kerkhof PC, Griffiths CE, Reich K, Leonardi CL, Blauvelt A, Tsai TF, Gong Y, Huang J, Papavassilis C, Fox T. Secukinumab long-term safety experience: a pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis. J Am Acad Dermatol. 2016;75(1):83–98 e84.  https://doi.org/10.1016/j.jaad.2016.03.024.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Michael P. Lee
    • 1
  • Kevin K. Wu
    • 2
  • Jashin J. Wu
    • 3
  1. 1.Eastern Virginia Medical SchoolNorfolkUSA
  2. 2.Frank H. Netter MD School of Medicine at Quinnipiac UniversityNorth HavenUSA
  3. 3.Founder and CEODermatology Research and Education FoundationIrvineUSA

Personalised recommendations